Influence of allogeneic effect on 7,12-dimethylbenz(alpha)anthracene carcinogenesis in mice.
Charles River mice either untreated or treated at birth with 7,12-dimethylbenz]alpha[anthracene (DMBA) were given allogeneic spleen cells from adult C57BL/Cas donors. These spleen cells were given as a single injection to mice at birth or at 7 or 14 days of age. Allogeneic treatment of mice at birth significantly increased the incidence of DMBA-induced lymphomas and shortened the latency period of the tumors. The incidence of subcutaneous tumors was moderately increased in DMBA-treated mice given grafts of allogeneic cells at 7 days of age. Lung tumors appeared to be decreased in the group given DMBA at birth and allogeneic cells 14 days later. Treatment with only allogeneic cells gave results essentially similar to those observed in untreated controls.
D015127:9,10-Dimethyl-1,2-benzanthracene; D000367:Age Factors; D000818:Animals; D000831:Animals, Newborn; D006087:Graft vs Host Reaction; D008223:Lymphoma / Q000139:chemically induced / Q000276:immunology; D051379:Mice; D008810:Mice, Inbred C57BL; D009368:Neoplasm Transplantation; D009374:Neoplasms, Experimental / Q000139:chemically induced / Q000276:immunology*; D013154:Spleen / Q000276:immunology; D014184:Transplantation, Homologous
D015127:9,10-Dimethyl-1,2-benzanthracene